EVENTS

Cardiovascular disease (CVD) in women evolves across the lifespan, shaped by reproductive biology, hormonal transitions, and social and environmental influences. A life-course framework highlights pregnancy and menopause as two critical points where cardiovascular risk is either revealed or accelerated. These windows provide important opportunities for early detection, targeted prevention, and improved clinical trial design. However, significant gaps persist, including the underrepresentation of pregnant and perimenopausal women in trials, limited randomized evidence, and a lack of longitudinal studies that track risk across decades.

Reframing lifespan transitions as strategic opportunities for detection and intervention can enable a proactive, lifespan-based approach to prevention and improve cardiovascular outcomes.

Date and time: December 7, 2-4pm ET
Location: Global CVCT Forum, The Mayflower Hotel, Washington DC

Discussion topics

• Current and future unmet needs in women’s cardiovascular health research.
• Global priorities and funding opportunities for advancing women’s cardiovascular research.
• Peripartum and Postpartum interventions to improve short- and long-term maternal and fetal cardiovascular health.
• Trials’ opportunities in menopause as a vascular transition.
• Ischemia with no obstructive coronary artery disease: A female-enriched phenotypes in HFpEF trials?
• Obesity–metabolic trials in women.
• Regulatory expectations for sex-specific evidence.
• Industry viewpoints.
• Patient Viewpoints.

About the Global CVCT Forum

The Global CVCT Forum brings together the people shaping cardiovascular clinical trials, including clinicians, researchers, patients and advocates, regulators, industry, statisticians, methodologists, journal editors, and other stakeholders. The meeting takes a multidisciplinary, discussion-led approach to clinical trial science, focusing on major trials, evidence generation, regulation, methodology, and translating research into better patient care.